Immunome Inc
IMNM19.329USD
-1.081-5.30%
Market hours （ET）Quotes delayed by 15 min
179.42MMarket Cap
LossP/E TTM
More Details of Immunome Inc Company
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Immunome Inc Info
Ticker SymbolIMNM
Company nameImmunome Inc
IPO dateOct 02, 2020
CEOSiegall (Clay B)
Number of employees118
Security typeOrdinary Share
Fiscal year-endOct 02
Address18702 N. Creek Parkway
CityBOTHELL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98011
Phone16103213700
Websitehttps://immunome.com/
Ticker SymbolIMNM
IPO dateOct 02, 2020
CEOSiegall (Clay B)
Company Executives of Immunome Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
665.25K
-21.27%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-31.96%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+58.18%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
38.41K
+5.21%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
37.73K
-7.95%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
665.25K
-21.27%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-31.96%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+58.18%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
38.41K
+5.21%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
37.73K
-7.95%
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 21
Updated: Sat, Feb 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.62%
T. Rowe Price Investment Management, Inc.
11.86%
Point72 Asset Management, L.P.
6.22%
BlackRock Institutional Trust Company, N.A.
5.61%
The Vanguard Group, Inc.
5.32%
Other
56.36%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.62%
T. Rowe Price Investment Management, Inc.
11.86%
Point72 Asset Management, L.P.
6.22%
BlackRock Institutional Trust Company, N.A.
5.61%
The Vanguard Group, Inc.
5.32%
Other
56.36%
Shareholder Types
Shareholders
Proportion
Investment Advisor
55.36%
Investment Advisor/Hedge Fund
26.30%
Hedge Fund
14.37%
Corporation
6.35%
Research Firm
3.91%
Venture Capital
2.09%
Individual Investor
1.14%
Bank and Trust
0.35%
Pension Fund
0.21%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
349
92.88M
84.18%
+6.06M
2025Q3
328
84.54M
92.66%
-1.54M
2025Q2
326
85.20M
99.48%
+13.79M
2025Q1
320
89.38M
113.71%
+17.13M
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
13.06M
11.83%
+6.89M
+111.70%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
10.64M
9.65%
+2.23M
+26.45%
Oct 31, 2025
Point72 Asset Management, L.P.
4.82M
4.37%
+138.70K
+2.96%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.24M
4.75%
+66.16K
+1.28%
Sep 30, 2025
The Vanguard Group, Inc.
4.88M
4.42%
+368.67K
+8.18%
Sep 30, 2025
Redmile Group, LLC
5.02M
4.55%
+151.16K
+3.10%
Sep 30, 2025
Enavate Sciences GP, LLC
4.77M
4.32%
--
--
Dec 18, 2025
PRIMECAP Management Company
3.02M
2.74%
-2.20K
-0.07%
Sep 30, 2025
State Street Investment Management (US)
2.80M
2.54%
+283.06K
+11.23%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.62%
Tema Oncology ETF
1.97%
WisdomTree BioRevolution Fund
1.53%
Virtus LifeSci Biotech Clinical Trials ETF
1.11%
ALPS Medical Breakthroughs ETF
0.55%
State Street SPDR S&P Biotech ETF
0.34%
iShares Micro-Cap ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
iShares Russell 2000 Growth ETF
0.07%
iShares US Tech Breakthrough Multisector ETF
0.06%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.62%
Tema Oncology ETF
Proportion1.97%
WisdomTree BioRevolution Fund
Proportion1.53%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.11%
ALPS Medical Breakthroughs ETF
Proportion0.55%
State Street SPDR S&P Biotech ETF
Proportion0.34%
iShares Micro-Cap ETF
Proportion0.24%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.21%
iShares Russell 2000 Growth ETF
Proportion0.07%
iShares US Tech Breakthrough Multisector ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
